1-5 of 5
Authors: David Kallend
Save search
Sort by
Journal Article

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

PDF
Frederick Raal and others
European Heart Journal, Volume 44, Issue 40, 21 October 2023, Pages 4272–4280, https://doi.org/10.1093/eurheartj/ehad596
Published: 28 August 2023
Journal Article

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

PDF
Kausik K Ray and others
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5047–5057, https://doi.org/10.1093/eurheartj/ehac615
Published: 04 November 2022
Journal Article

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial Get access

PDF
Kausik K. Ray and others
European Heart Journal, Volume 35, Issue 27, 14 July 2014, Pages 1792–1800, https://doi.org/10.1093/eurheartj/ehu105
Published: 17 March 2014
Journal Article
EDITOR'S CHOICE FAST TRACK

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Get access

PDF
Thomas F. Lüscher and others
European Heart Journal, Volume 33, Issue 7, April 2012, Pages 857–865, https://doi.org/10.1093/eurheartj/ehs019
Published: 16 February 2012
Journal Article
EDITOR'S CHOICE

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

PDF
Evan A. Stein and others
European Heart Journal, Volume 31, Issue 4, February 2010, Pages 480–488, https://doi.org/10.1093/eurheartj/ehp601
Published: 22 January 2010